Export 94 results:
Author Title Type [ Year(Asc)]
Filters: Author is Serge Gauthier  [Clear All Filters]
Mortby ME, Black SE, Gauthier S, Miller D, Porsteinsson A, Smith EE, Ismail Z.  2018.  Dementia clinical trial implications of mild behavioral impairment.. Int Psychogeriatr. 30(2):171-175.
Pascoal TA, Shin M, Kang MSu, Chamoun M, Chartrand D, Mathotaarachchi S, Bennacef I, Therriault J, Ng KPin, Hopewell R et al..  2018.  In vivo quantification of neurofibrillary tangles with [F]MK-6240.. Alzheimers Res Ther. 10(1):74.
Gauthier S, Herrmann N, Rosa-Neto P.  2018.  Optimal use of cholinergic drugs in Alzheimer's disease.. Brain.
Wilcock GK, Gauthier S, Frisoni GB, Jia J, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Schelter BO, Wischik DJ et al..  2018.  Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.. J Alzheimers Dis. 61(1):435-457.
Villeneuve S, Vogel JW, Gonneaud J, Binette APichet, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS et al..  2018.  Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.. JAMA Neurol.
Schilling LPorcello, Pascoal TA, Zimmer ER, Mathotaarachchi S, Shin M, Rieder CRoberto de, Gauthier S, Palmini A, Rosa-Neto P.  2018.  Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia.. Mol Neurobiol.
Gauthier S, Ng KPin, Pascoal TA, Zhang H, Rosa-Neto P.  2018.  Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment.. J Alzheimers Dis.
Benedet AL, Yu L, Labbe A, Mathotaarachchi S, Pascoal TA, Shin M, Kang M-S, Gauthier S, Rouleau GA, Poirier J et al..  2018.   variant mitigates Alzheimer disease pathophysiology in vivo and postmortem.. Neurol Genet. 4(1):e216.
Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim H-I, Gauthier S, Pellerin L, Hamel E, Rosa-Neto P.  2017.  [(18)F]FDG PET signal is driven by astroglial glutamate transport.. Nat Neurosci. 20(3):393-395.
Lajoie I, Nugent S, Debacker C, Dyson K, Tancredi FB, Badhwar AP, Belleville S, Deschaintre Y, Bellec P, Doyon J et al..  2017.  Application of calibrated fMRI in Alzheimer's disease.. Neuroimage Clin. 15:348-358.
Gauthier S, Ng KPin, Pascoal TA, Mathotaarachchi S, Chung C-O, Benedetti AL, Shin M, Kang MSu, Li X, Ba M et al..  2017.  Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 89(18):1931.
Brayet P, Petit D, Baril A-A, Gosselin N, Gagnon J-F, Soucy J-P, Gauthier S, Kergoat M-J, Carrier J, Rouleau I et al..  2017.  Brain perfusion during rapid-eye-movement sleep successfully identifies amnestic mild cognitive impairment.. Sleep Med. 34:134-140.
Jia J, Gauthier S, Pallotta S, Ji Y, Wei W, Xiao S, Peng D, Guo Q, Wu L, Chen S et al..  2017.  Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer's disease.. Alzheimers Dement. 13(5):592-597.
Schoemaker D, Poirier J, D Collins L, Gauthier S, Pruessner JC.  2017.  Familiarity deficits in cognitively normal aging individuals with APOE ε4: A follow-up investigation of medial temporal lobe structural correlates.. Alzheimers Dement (Amst). 9:21-24.
Maria Rajah N, Wallace LMK, Ankudowich E, Yu EH, Swierkot A, Patel R, Chakravarty MM, Naumova D, Pruessner J, Joober R et al..  2017.  Family history and APOE4 risk for Alzheimer's disease impact the neural correlates of episodic memory by early midlife.. Neuroimage Clin. 14:760-774.
Mathotaarachchi S, Pascoal TA, Shin M, Benedet AL, Kang MSu, Beaudry T, Fonov VS, Gauthier S, Rosa-Neto P.  2017.  Identifying incipient dementia individuals using machine learning and amyloid imaging.. Neurobiol Aging. 59:80-90.
Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, Gauthier S, Geda YE, Herrmann N, Kanji J et al..  2017.  The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations.. J Alzheimers Dis. 56(3):929-938.
Ng KPin, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MSu, Shin M, Guiot M-C, Guo Q, Harada R, Comley RA et al..  2017.  Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain.. Alzheimers Res Ther. 9(1):25.
Bergeron D, Flynn K, Verret L, Poulin S, Bouchard RW, Bocti C, Fülöp T, Lacombe G, Gauthier S, Nasreddine Z et al..  2017.  Multicenter Validation of an MMSE-MoCA Conversion Table.. J Am Geriatr Soc. 65(5):1067-1072.
Parent MJ, Zimmer ER, Shin M, Kang MSu, Fonov VS, Mathieu A, Aliaga A, Kostikov A, Carmo SDo, Dea D et al..  2017.  Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.. J Neurosci. 37(50):12263-12271.
Ng KPin, Pascoal TA, Mathotaarachchi S, Chung C-O, Benedet AL, Shin M, Kang MSu, Li X, Ba M, Kandiah N et al..  2017.  Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 88(19):1814-1821.
Ba M, Li X, Ng KPin, Pascoal TA, Mathotaarachchi S, Rosa-Neto P, Gauthier S.  2017.  The prevalence and biomarkers' characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database.. Alzheimers Dement (N Y). 3(1):107-113.
Gauthier S, Robillard J, de Champlain J.  2017.  Progress in transnational scientific and ethics review: Commentary on the proposal for a single North American review board for research on dementia.. Alzheimers Dement.
Schoemaker D, Mascret C, D Collins L, Yu E, Gauthier S, Pruessner JC.  2017.  Recollection and familiarity in aging individuals: Gaining insight into relationships with medial temporal lobe structural integrity.. Hippocampus. 27(6):692-701.
Gauthier S.  2017.  Research update on Alzheimer's disease and introduction to the Expert Review of Neurotherapeutics special issue.. Expert Rev Neurother. 17(1):1-2.